We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Ultrasound Technology Helps Dissolve Blood Clots

By MedImaging International staff writers
Posted on 19 Jun 2014
Print article
Image: The EkoSonic IDDC and removable coaxial ultrasound transducer core (Photo courtesy of EKOS Corporation).
Image: The EkoSonic IDDC and removable coaxial ultrasound transducer core (Photo courtesy of EKOS Corporation).
A new system allows controlled and selective infusion of physician-specified fluids, including thrombolytics, for the treatment of pulmonary embolism (PE).

The EkoSonic Endovascular System is an ultrasound-facilitated catheter-directed low-dose fibrinolysis device designed to gently accelerate the penetration of thrombolytic agents into a thrombus, providing high levels of lysis to minimize the risk of PE and intracranial hemorrhage. The system is intended for the treatment of patients with a 50% or more clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, as well as evidence of right heart dysfunction, based on a mean pulmonary artery pressure of 25 mmHg or higher, and/or echocardiographic evaluation.

The device consists of a multilumen intelligent drug delivery catheter (IDDC) with a removable coaxial ultrasound transducer core and a microsonic device (MSD). The acoustic energy conditions the clot by thinning fibrin and increasing porosity, creating a pressure gradient which transports the thrombolytic agent deep into the thrombus. As a result, there is no thrombus fracture or breakage, no damage to valves or the vascular wall, and no hemolysis.

An added benefit is that since red blood cells (RBCs) are not fractured during the procedure, there is no adenosine release and no additional compromise to renal function. The EkoSonic Endovascular System is a product of EKOS Corporation (Bothell, WA, USA), and has been approved by the US Food and Drug Administration (FDA).

“The EKOS clinical data established that patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with the EkoSonic system,” said Prof. Samuel Goldhaber, MD, director of the Thrombosis Research Group at Brigham and Woman’s Hospital (Boston, MA, USA). “This is the first FDA cleared treatment option for PE since the approval of the drug tissue plasminogen activator [tPA], in 1990.”

“Interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use our system to provide faster, safer and more complete dissolution of thrombus,” said Matt Stupfel, General Manager of EKOS. “We are proud to have completed the world’s only randomized controlled trial and the largest prospective single-arm trial on the safety and effectiveness of EKOS therapy in the treatment of PE. The positive outcomes of those trials, combined with our expanded indication will allow a better standard of care for thousands of patients who suffer from PE.”

Related Links:

EKOS Corporation


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Needle Guide
Ultra-Pro II
Digital Radiography Acquisition Software
VXvue with PureImpact
New
Ultrasound Table
Powered Ultrasound Table-Flat Top

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.